中国癌症杂志 ›› 2017, Vol. 27 ›› Issue (2): 121-127.doi: 10.19401/j.cnki.1007-3639.2017.02.007

• 论著 • 上一篇    下一篇

ICAM-1在三阴性乳腺癌中的表达的临床意义及与预后的关系

刘子梅,余文熙,孙 矗,袁 媛,沈 赞   

  1. 上海交通大学附属第六人民医院肿瘤内科,上海 200233
  • 出版日期:2017-02-28 发布日期:2017-03-22
  • 通信作者: 沈 赞 E-mail:sshenzzan@vip.sina.com
  • 基金资助:
    国家自然科学基金面上项目(30872991)。

Clinical significance of ICAM-1 expression and its correlation with prognosis of triple-negative breast cancer

LIU Zimei, YU Wenxi, SUN Chu, YUAN Yuan, SHEN Zan   

  1. Department of Medical Oncology, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai 200233, China
  • Published:2017-02-28 Online:2017-03-22
  • Contact: SHEN Zan E-mail: sshenzzan@vip.sina.com

摘要: 背景与目的:三阴性乳腺癌(triple-negative breast cancer,TNBC)侵袭性强,预后差,治疗手段匮乏。该研究通过检测人TNBC与对应癌旁组织中细胞间黏附分子-1(intercellular adhesion molecule-1,ICAM-1)蛋白的表达,研究ICAM-1蛋白与TNBC临床病理特征及预后的相关性。方法:收集59例TNBC及其对应的50例癌旁组织标本,应用免疫组织化学法检测ICAM-1在59例TNBC及50例癌旁组织中的表达水平,比较其阳性率。分析ICAM-1蛋白的表达与TNBC年龄、肿瘤大小、临床病理类型、组织学分级、淋巴结转移、肿瘤TNM分期、脉管癌栓、神经浸润、Ki-67、p53和E-cadherin等临床病理特征及与患者预后的关系。结果:TNBC中ICAM-1的表达明显高于癌旁组织(P=0.000)。ICAM-1与淋巴转移、组织学分级和TNM分期有关(P分别为0.036、0.027和0.048),与肿瘤大小、临床病理类型、脉管癌栓、Ki-67水平、p53和E-cadherin表达等无关。ICAM-1高表达组患者的无病生存时间(disease-free survival,DFS)显著较ICAM-1低表达组短(P=0.036),但对于总生存时间(overall survival,OS)没有显著影响。另外,Cox比例风险模型多因素分析,ICAM-1表达、淋巴结转移是影响DFS的独立危险因素(HR=3.2,95%CI:1.6-6.4,HR=2.7,95%CI:1.3-5.9,P均<0.05)。结论:ICAM-1蛋白可以作为判断TNBC恶性程度的指标,ICAM-1高表达的三阴性乳腺癌临床预后差。

关键词: 三阴性乳腺癌, 细胞间黏附分子-1, 免疫组化, 预后

Abstract: Background and purpose: Triple negative breast cancer (TNBC) is with high invasion, poor prognosis and lack of usefull treatment. This study investigated expression status of ICAM-1 protein in TNBC in order to explore its relationship with clinicopathological features and outcome in patients. Methods: Fifty-nine tissue samples of TNBC were collected while 50 cases of para-carcinoma tissue samples were used as negative controls. Immunohistochemical staining was conducted to detect expression level of ICAM-1 protein. The relationship of ICAM-1 protein expression with clinicopathological features (age, tumor size, subtype, grade, status of lymph node metastasis, TNM stage, vascular tumor thrombus, nerve infiltration, Ki-67, p53 and E-cadherin expression) and outcome in patients were analyzed. Results: The ICAM-1 protein expression of TNBC was significantly higher than that in adjacent tissues (P=0.000). ICAM-1 expression was related to status of lymph node metastasis, grade and TNM stage (with a P-value of 0.036, 0.027 and 0.048, respectively), while demonstrated an undefined relationship with tumor size, subtype, vascular tumor thrombus and expression of Ki-67, p53 and E-cadherin. The disease-free survival (DFS) of ICAM-1 high expression set was shorter than that of the lower one but has nothing to do with overall survival (OS). In addition, Cox proportional hazards model showed that ICAM-1 expression and lymph node metastasis were independent risk factors of DFS in patients (HR=3.2, 95%CI: 1.6 to 6.4, HR=2.7, 95%CI: 1.28 to 5.9, P<0.05). Conclusion: ICAM-1 could serve as a predictive factor for differentiation status of TNBC. The high expression of ICAM-1 in TNBC may indicate poorer prognosis.

Key words: Triple-negative breast cancer, Intercellular adhesion molecule-1, Immunohistochemistry, Prognosis